Zotepine

• IUPAC: 2 - (8- Chlordibenzo [b, f] thiepin -10 -yloxy )-N, N- dimethylethylamine

N05AX11

Colorless crystals

Atypical Antipsychotics

90-91 ° C

Attention

306 mg · kg -1 ( LD50, rat, oral)

Template: Infobox chemical / molecular formula search available

Zotepine is a drug that is used for the treatment of psychoses of the schizophrenic. Pharmacologically it belongs to the class of atypical antipsychotics, chemically it is one of the Dibenzepinen. The plasma half-life of zotepine in humans is about 12 hours.

Indication

Zotepine is indicated for the treatment of psychoses from the schizophrenic.

Application

The daily dose is administered in multiple doses. In hepatic insufficiency, renal impairment and elderly patients the dose should be reduced according to the degree of illness. In patients with epilepsy and epileptiform seizures in the history Zotepine should be like other neuroleptics, used cautiously. With worsening of epilepsy ( seizure frequency increases, worsening the severity of the seizures, etc. ) may be a dose adjustment is required.

Contraindications

Zotepine may not be applied to a hypersensitivity to the active substance or to structurally similar substances, such as neuroleptics from phenothiazine and thioxanthene type. Even in cases of acute intoxication with psychotropic drugs, alcohol, or opiates, an impairment of the blood-forming ( hematopoietic ) system as well as during pregnancy and lactation therapy is contraindicated with zotepine. Due to lack of therapeutic experience, children under 18 years are excluded from treatment with zotepine.

Side effects

Are frequent fatigue, occasional dizziness, headache, and changes in the EEG. In disposition, patients, particularly at higher doses, epileptiform seizures may occur. Very rarely, malignant neuroleptic syndrome developed ( with fever, rigors, akinesia, vegetative derailment, clouding of consciousness up to coma ).

→ Main article: Atypical Antipsychotics

Trade names

Zotepine was in Germany and Austria under the name Nipolept commercially available.

On September 1, 2010, the Sanofi -Aventis GmbH, a distribution of Nipolept because they could no longer obtain raw materials, which was the quality requirements.